Saturday 17 October 2026 Export AZTA’s income statement to Excel — free account

Azenta, Inc.

AZTA Healthcare Medical Instruments & Supplies

Azenta, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $593.8 million, up 3.55% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS grew 104.4% and free cash flow fell 134.7%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

34.09 2.43 −6.65%

Follow AZTA

Alert me

Market cap: $1.6B
P/E: 0.0×
Fwd P/E: −6.2×
Dividend yield: —
F-score: 7/9
Altman Z: 3.85
Beneish M: −2.63
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.17

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	—	1	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 4.78%

Capital & Financial Ratios $m

Market Cap 1,600.00

Revenue 613.81

Net Income (122.90)

Free Cash Flow 9.88

Net Debt (328.21)

Current Ratio 2.50

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (6.20)

P/S ratio 2.52

P/B ratio 1.02

Past 5Y EPS Growth —

This Y EPS Growth (36.00%)

Next Y EPS Growth 60.09%

Next Y revenue growth 3.58%

Next 5Y EPS Growth 12.53%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 19.87%

10-year low 10-year high

P/B against its own 10 years 16.44%

10-year low 10-year high

EV/Sales against its own 10 years 19.57%

10-year low 10-year high

EV/FCF against its own 10 years 90.15%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	0.40	0.10 0.10 0.10 0.10
2020	0.40	0.10 0.10 0.10 0.10
2019	0.40	0.10 0.10 0.10 0.10
2018	0.40	0.10 0.10 0.10 0.10
2017	0.40	0.10 0.10 0.10 0.10
2016	0.40	0.10 0.10 0.10 0.10

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,022	433	343	328
Receivables	157	178	152	150
Inventory	128	71	75	79
Other	13	99	74	71
	1,419	833	708	681

	2023	2024	2025	Q'26
Payables	36	33	38	39
ST’ Debt	—	—	—	—
Other	158	32	62	58
	211	206	238	273

Compound Annual Growth %

	10y	5y	3y
Sales	0.72%	8.85%	2.25%
Cash Flow	5.14%	13.77%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	10.57%	7.31%	(19.92%)

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	149	145	161	—	—
’25	147	143	144	159	594
’24	142	136	144	151	573
’23	178	148	166	59	551
’22	140	146	133	138	555
’21	118	130	129	137	514
’20	211	220	220	(263)	389

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	21	14	1	—	—
’25	30	14	26	2	72
’24	14	9	10	18	50
’23	(27)	(12)	17	28	6
’22	16	(71)	(420)	10	(466)
’21	44	34	45	27	150
’20	26	(66)	26	52	38

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	15	6	(5)	—	—
’25	22	7	15	(6)	38
’24	2	0	1	8	12
’23	(40)	(21)	9	18	(34)
’22	(3)	(101)	(435)	(4)	(543)
’21	29	24	36	9	97
’20	16	(77)	18	42	(2)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.34)	(3.49)	0.05	—	—
’25	(0.29)	(0.88)	(1.15)	1.02	(1.30)
’24	(0.28)	(2.47)	(0.12)	(0.10)	(3.09)
’23	(0.15)	(0.07)	(0.02)	0.06	(0.22)
’22	0.58	28.15	(0.13)	(0.28)	28.48
’21	0.35	0.32	0.53	0.29	1.49
’20	0.18	0.12	0.19	0.39	0.88

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	8.33	16.51	22.87	24.15	21.19	65.37	37.61	36.01	38.82	23.91	Analyst estimates 2026–2028 Powerpack
	High	17.98	34.77	39.75	50.35	77.44	124.79	104.64	66.98	69.16	55.64
People
People	Employees	1,310	1,661	1,548	2,984	3,200	2,800	3,100	3,500	3,300	3,000
	Revenue/emp, $m	0.33	0.32	0.41	0.11	0.12	0.18	0.18	0.16	0.17	0.20
Income, $m
Income, $m	Revenue	434	527	632	334	389	514	555	551	573	594
	Gross margin, %	36.10	37.70	38.96	40.28	44.31	47.46	46.01	43.38	44.40	45.52
	EBT	(18)	15	20	(84)	(40)	(49)	(10)	(20)	(19)	(7)
	EBT margin, %	(4.18)	2.75	3.24	(25.12)	(10.37)	(9.53)	(1.79)	(3.63)	(3.34)	(1.20)
	Net income	(69)	63	116	437	65	111	2,133	(15)	(165)	(56)
	Depreciation	28	28	38	56	66	66	52	78	201	60
Per share, $
Per share, $	Revenue	6.34	7.58	8.96	4.64	5.28	6.92	7.42	8.32	10.78	12.98
	Earnings	(1.01)	0.90	1.65	6.08	0.88	1.49	28.48	(0.22)	(3.09)	(1.30)
	Cash flow	0.58	1.38	1.05	1.26	0.51	2.02	(6.22)	0.09	0.94	1.58
	Capex	(0.15)	(0.18)	(0.18)	(0.33)	(0.54)	(0.71)	(1.03)	(0.60)	(0.70)	(0.74)
	Free cash flow	0.43	1.20	0.87	0.93	(0.03)	1.31	(7.26)	(0.51)	0.23	0.84
	Book value	8.08	8.73	10.18	15.82	16.50	17.85	44.91	38.25	33.25	37.75
	Shares, m	69	70	70	72	74	74	75	66	53	46
Valuation, ×
Valuation, ×	P/E	0.00	34.69	20.89	6.11	52.57	68.69	1.51	0.00	0.00	0.00
	P/S	2.15	4.12	3.85	7.98	8.76	14.81	5.78	5.98	4.49	2.21
	P/B	1.68	3.57	3.38	2.34	2.80	5.74	0.95	1.30	1.46	0.76
	EV/Sales	1.97	3.94	3.77	7.13	8.24	14.45	2.35	4.22	3.82	1.72
	EV/FCF	28.95	24.87	38.81	35.52	(1,556.10)	76.49	(2.41)	(69.20)	177.53	26.63
Cash, $m
Cash, $m	Operating cash flow	40	96	74	91	38	150	(466)	6	50	72
	Capex	(10)	(13)	(13)	(24)	(40)	(53)	(77)	(39)	(37)	(34)
	Free cash flow	30	83	61	67	(2)	97	(543)	(34)	12	38
Balance, $m
Balance, $m	Working capital	180	205	399	375	438	432	2,229	1,208	627	471
	Total debt	—	—	196	51	50	50	56	72	—	—
	Net debt	(85)	(102)	(48)	(285)	(200)	(185)	(1,953)	(1,022)	(433)	(343)
	Shareholders’ equity	554	608	718	1,139	1,214	1,325	3,363	2,535	1,768	1,727
Returns, %
Returns, %	ROA	(9.62)	8.62	12.52	33.50	4.22	6.56	77.06	(0.44)	(6.61)	(2.68)
	ROIC	(2.27)	1.77	2.93	(3.47)	(2.26)	(1.70)	(1.10)	(2.53)	(2.40)	(1.21)
	ROE	(11.72)	10.78	17.59	47.12	5.51	8.72	90.98	(0.50)	(7.67)	(3.19)

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NVST Envista Holdings Corporation	$3.8B	38.8×	24.4×	+7.10% (above 0%: growing)	+106.25% (above 0%: growing)	+37.57% (above 0%: growing)	55.72%	10.99%	Compare
PLSE Pulse Biosciences, Inc	$3.3B	— (loss-making)	— (loss-making)	+4,922.22% (above 0%: growing)	n/m	−45.39% (below 0%: shrinking)	37.10%	(5,823.04%)	Compare
WRBY Warby Parker Inc.	$3.0B	334×	122×	+9.81% (above 0%: growing)	n/m	−71.75% (below 0%: shrinking)	57.94%	1.34%	Compare
ATRC AtriCure, Inc.	$2.9B	259×	591×	+12.83% (above 0%: growing)	n/m	−2.79% (below 0%: shrinking)	77.23%	6.29%	Compare
LMAT LeMaitre Vascular, Inc.	$1.9B	27.9×	31.5×	+9.57% (above 0%: growing)	+22.95% (above 0%: growing)	−27.95% (below 0%: shrinking)	72.13%	28.98%	Compare
XRAY DENTSPLY SIRONA Inc.	$1.8B	— (loss-making)	27.0×	−4.06% (below 0%: shrinking)	n/m	+252.94% (above 0%: growing)	54.90%	9.13%	Compare
KMTS Kestra Medical Technologies, Ltd.	$1.7B	— (loss-making)	— (loss-making)	+59.88% (above 0%: growing)	n/m	−17.75% (below 0%: shrinking)	56.50%	(121.59%)	Compare
AZTA Azenta, Inc.	$1.6B	— (loss-making)	— (loss-making)	+12.04% (above 0%: growing)	n/m	−134.69% (below 0%: shrinking)	44.89%	(2.59%)
STAA STAAR Surgical Company	$1.1B	304×	103×	+111.04% (above 0%: growing)	n/m	+166.10% (above 0%: growing)	74.55%	10.80%	Compare
Median of peers	$2.4B	259×	67.3×	+11.32%	—	−10.27%	57.22%	7.71%

All 55 Medical Instruments & Supplies stocks →

Azenta, Inc. (AZTA) key facts

Strength: Azenta, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $593.8 million, up 3.55% from fiscal 2024.
Azenta, Inc. (AZTA) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AZTA traded at $34.09, a market capitalization of $1.6 billion.
Return on equity was −3.19% and debt-to-equity 0.00.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 3.85 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.